UBS Positive on InnoCare Pharma's Collaboration with Eli Lilly on Novel Target Programs

Stock News

Sep 25

UBS has issued a research report maintaining a "Buy" rating on InnoCare Pharma (09969) with a target price of HK$21.8.

InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to discover and develop up to five novel target programs, a development UBS views positively as recognition of the company's research and development capabilities.

The bank noted that upfront and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties on net sales at a single-digit percentage rate.

According to management, all programs will commence from the drug discovery stage. The related payments could provide upside potential to revenue and net profit in 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1132866662"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1132866662\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1132866662?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-25 17:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132866662","market":"nz","top_or_hot":-1,"title":"UBS Positive on InnoCare Pharma's Collaboration with Eli Lilly on Novel Target Programs","media":"Stock News","content":"<p>UBS has issued a research report maintaining a \"Buy\" rating on <b>InnoCare Pharma (09969)</b> with a target price of HK$21.8.<br><br><b>InnoCare Pharma</b> has entered into a collaboration with <b>Eli Lilly (LLY.US)</b> to discover and develop up to five novel target programs, a development UBS views positively as recognition of the company's research and development capabilities.<br><br>The bank noted that upfront and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties on net sales at a single-digit percentage rate.<br><br>According to management, all programs will commence from the drug discovery stage. The related payments could provide upside potential to revenue and net profit in 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Positive on InnoCare Pharma's Collaboration with Eli Lilly on Novel Target Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Positive on InnoCare Pharma's Collaboration with Eli Lilly on Novel Target Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-25 17:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS has issued a research report maintaining a \"Buy\" rating on <b>InnoCare Pharma (09969)</b> with a target price of HK$21.8.<br><br><b>InnoCare Pharma</b> has entered into a collaboration with <b>Eli Lilly (LLY.US)</b> to discover and develop up to five novel target programs, a development UBS views positively as recognition of the company's research and development capabilities.<br><br>The bank noted that upfront and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties on net sales at a single-digit percentage rate.<br><br>According to management, all programs will commence from the drug discovery stage. The related payments could provide upside potential to revenue and net profit in 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"","article_id":"1132866662","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132866662","pubTimestamp":1790327777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UBS has issued a research report maintaining a \"Buy\" rating on InnoCare Pharma (09969) with a target price of HK$21.8.InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK0239":"医药制造","BK1161":"生物科技","BK1574":"生物医药B类股","09969":"诺诚健华"},"translate_title":"瑞银对诺诚健华与礼来公司在新型目标项目上的合作持积极态度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":1},"content_text":"UBS has issued a research report maintaining a \"Buy\" rating on InnoCare Pharma (09969) with a target price of HK$21.8.InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to discover and develop up to five novel target programs, a development UBS views positively as recognition of the company's research and development capabilities.The bank noted that upfront and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties on net sales at a single-digit percentage rate.According to management, all programs will commence from the drug discovery stage. The related payments could provide upside potential to revenue and net profit in 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}